You are here: Industry Insights > AbbVie

News List

AbbVie's immunology blockbuster-to-be Skyrizi picks up first global approval fiercepharma
March 27, 2019
As Humira heads toward the end of its exclusive life in the U.S. and faces new competition in Europe, AbbVie is set for its next blockbuster launch thanks to an approval in Japan.
FDA warns doctors, myeloma patients of doubled death risk from AbbVie, Roche's Venclexta fiercepharma
March 23, 2019
Earlier this month, the FDA halted enrollment in multiple myeloma clinical trials featuring AbbVie and Roche drug Venclexta.
AbbVie faces class action lawsuit from New York grocery union over Humira 'patent thicket' fiercepharma
March 21, 2019
AbbVie’s efforts to protect its megablockbuster Humira have been well documented and much maligned……
Venclexta trial deaths force AbbVie, Roche to stop recruiting myeloma patients fiercepharma
March 20, 2019
AbbVie and Roche are looking to move key oncology drug Venclexta deeper into the blood cancer arena, but their ambitions in multiple myeloma just took a hit.
Louisiana's 'Netflix' deal for hepatitis C drugs wins bids from AbbVie, Gilead and Merck fiercepharma
March 11, 2019
States across the U.S. have taken on high drug prices with new laws, proposals and Medicaid rules, many of them unpopular with the pharma industry. Not so in Louisiana, where a “Netflix” payment model for hepatitis C drugs has top players eager to partici
Global HCV Drug Market Declined to below USD10 Billion in 2018, with only AbbVie’s Mavyret Outshining PharmaSources/1℃
March 11, 2019
The global HCV drug market continued to shrink and reached USD7.767 billion in 2018.
AbbVie and Pfizer return to the top of pharma's TV spending list for February fiercepharma
March 08, 2019
AbbVie’s Humira is back—at the top of the pharma TV ad spending pile, that is. In February, Humira was the No. 1 spender again, according to data from real-time TV ad tracker iSpot.tv, swapping places with Pfizer’s Xeljanz.
Louisiana's 'Netflix' deal for hepatitis C drugs wins bids from AbbVie, Gilead and Merck fiercepharma
March 08, 2019
States across the U.S. have taken on high drug prices with new laws, proposals and Medicaid rules, many of them unpopular with the pharma industry.
AbbVie and Pfizer return to the top of pharma's TV spending list for February fiercepharma
March 07, 2019
AbbVie’s Humira is back—at the top of the pharma TV ad spending pile, that is. In February, Humira was the No. 1 spender again, according to data from real-time TV ad tracker iSpot.tv, swapping places with Pfizer’s Xeljanz.
AbbVie and Pfizer return to the top of pharma's TV spending list for February fiercepharma
March 07, 2019
AbbVie’s Humira is back—at the top of the pharma TV ad spending pile, that is. In February, Humira was the No. 1 spender again, according to data from real-time TV ad tracker iSpot.tv, swapping places with Pfizer’s Xeljanz.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page